跳至主要内容
临床试验/NCT00272805
NCT00272805已完成3 期

Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction

Cardiovascular Clinical Sciences Inc104 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2005年10月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
400
试验地点
104
主要终点
Dosing compliance: pill taking total taken vs number prescribed

研究概览

简要总结

The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.

详细描述

Study Further Study Details:

Primary outcome: pill-taking compliance (total doses taken versus total doses prescribed)

Expected Total Enrollment: 400 subjects at 56 study sites in the U.S.

Study Start: October 2005

This is a 5-month double-blind treatment study of male and female subjects with stable mild-to-severe chronic heart failure and with left ventricular dysfunction with symptoms of heart failure.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to read English
  • Stable symptoms of mild to severe heart failure
  • Stable medical regimen for heart failure
  • On a stable dose of Coreg for at least 2 months
  • LVEF ≤40% within the previous 24 months

排除标准

  • Uncorrected obstructive or regurgitant valve disease
  • Complex congenital heart disease
  • Recent ICD or pacemaker placement
  • Recent coronary artery bypass surgery or stroke
  • Candidate for heart transplanct within 5 months of study start
  • Present or planned use of MAO inhibitors, alfpha-blockers, combined alpha-beta blockers, any Class I/II anti-arrythmnic agents, (amiodarone may be used if ≤ 200mg/day). Use of intravenous vasodilator/inotropic agents.

结局指标

主要结局

Dosing compliance: pill taking total taken vs number prescribed

次要结局

  • quality of life

研究者

发起方
Cardiovascular Clinical Sciences Inc
申办方类型
Industry
责任方
Sponsor

研究点 (104)

Loading locations...

相似试验